Velentium vs Phillips-Medisize: full comparison for 2026
Quick verdict
Velentium (4.5/5) edges ahead of Phillips-Medisize (3.9/5) overall. Velentium is the better choice for implantables and FDA cybersecurity submissions. Phillips-Medisize is the stronger option for drug delivery devices needing high-volume production. The right choice depends on your project size, budget, and required tech stack.
Velentium vs Phillips-Medisize: head-to-head summary
| Criterion | Velentium | Phillips-Medisize |
|---|---|---|
| Founded | 2012 | 1964 |
| HQ | Katy, TX, USA | Hudson, WI, USA |
| Team size | 51–250 | ~7,000 |
| Rating | 4.5 / 5 | 3.9 / 5 |
| Primary differentiator | Combines active-implantable engineering with a dedicated device cybersecurity team that prepares FDA premarket security documentation | Design, molding and assembly of drug delivery devices under one global quality system |
| Pricing model | Fixed project, time and materials, manufacturing contract | Development contract plus manufacturing supply agreement |
| Min. engagement | Not disclosed | Not disclosed |
| Primary tech stack | Embedded C/C++, RTOS, BLE | Injection molding, Automated assembly, BLE |
| Industries served | Implantables & neuromodulation, Surgical & therapeutic devices, Wearables & remote monitoring | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
Velentium vs Phillips-Medisize: overview
Velentium
Velentium was founded in 2012 and is based in Katy, near Houston, Texas. It designs, develops and manufactures active medical devices, including implantables and their programmers, and offers systems engineering, firmware, software, cybersecurity and CGMP manufacturing. Great Point Partners completed a growth recapitalization in 2021, the company sold its oil and gas division in 2023 to focus fully on medtech, and it took $15M in growth financing from Trinity Capital in 2024. Headcount estimates range from 51 to 250.
Phillips-Medisize
Phillips-Medisize is a subsidiary of Molex, itself owned by Koch Industries, and provides outsourced design, development and manufacturing to pharma, diagnostics and medical device companies. It is based in Wisconsin and has about 7,000 employees. Molex's purchase of inhalation specialist Vectura added combination-product expertise, and the combined team includes more than 1,200 engineers and scientists across 30 sites. A $110M manufacturing campus in Katowice, Poland, opened in November 2023.
Services and capabilities: Velentium vs Phillips-Medisize
| Capability | Velentium | Phillips-Medisize |
|---|---|---|
| Electronics & PCB design | ✓ | ✓ |
| Firmware & embedded software | ✓ | ✗ |
| SaMD & companion apps | ✗ | ✗ |
| Connected devices & IoT | ✗ | ✗ |
| Industrial design & human factors | ✗ | ✗ |
| Mechanical engineering | ✗ | ✓ |
| Device cybersecurity | ✓ | ✗ |
| Regulatory & QMS support | ✓ | ✓ |
| Manufacturing & scale-up | ✓ | ✓ |
Tech stack comparison: Velentium vs Phillips-Medisize
| Framework / platform | Velentium | Phillips-Medisize |
|---|---|---|
| Embedded C/C++ | ✓ | N/A |
| Embedded Linux | N/A | N/A |
| RTOS | ✓ | N/A |
| BLE | ✓ | ✓ |
| Cloud (AWS/Azure) | N/A | N/A |
| IEC 62304 | ✓ | N/A |
| ISO 14971 | ✓ | N/A |
| ISO 13485 QMS | N/A | ✓ |
| Qt | N/A | N/A |
Pricing comparison: Velentium vs Phillips-Medisize
| Criterion | Velentium | Phillips-Medisize |
|---|---|---|
| Minimum engagement | Not disclosed | Not disclosed |
| Engagement models | Fixed project, Manufacturing contract, Time & materials | Fixed project, Manufacturing contract |
| Rate transparency | Not public | Not public |
| Price tier | Mid-market | Mid-market |
Target audience comparison: Velentium vs Phillips-Medisize
| Dimension | Velentium | Phillips-Medisize |
|---|---|---|
| Best company size | Startup to mid-market | Startup to mid-market |
| Best industries | Implantables & neuromodulation, Surgical & therapeutic devices, Wearables & remote monitoring | Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices |
| Best use cases | Building a neurostimulator and its clinician programmer, Preparing the cybersecurity section of an FDA 510(k) or PMA | Autoinjector or pen injector development and production, Inhaler device for a pharma combination product |
| Typical project type | Fixed project | Fixed project |
Velentium vs Phillips-Medisize: pros and cons
| Velentium | |
|---|---|
| + | Cybersecurity is a full practice here, covering threat modeling, SBOMs, testing and postmarket monitoring |
| + | Experience with active implantable devices, one of the hardest device categories to engineer and certify |
| + | Can manufacture Class II and III devices after development, reducing transfer risk |
| + | Offers training on device cybersecurity, which helps client teams keep up after hand-off |
| - | Private-equity recapitalization and debt financing mean ownership priorities may shift over time |
| - | Smaller than the large consultancies, so very broad programs may stretch the team |
| - | Industrial design and human factors are not its main strength |
| Phillips-Medisize | |
|---|---|
| + | Very large manufacturing footprint across the US, Europe and Asia |
| + | Vectura deal added deep inhalation and combination-product skills |
| + | Development and manufacturing under one quality system |
| + | Experience with connected drug delivery |
| - | Owned by Molex and Koch Industries, so it suits large pharma more than small startups |
| - | Development work is usually tied to a manufacturing agreement |
| - | Less suited to software-heavy or early research projects |
Who should choose Velentium?
A typical fit: building a neurostimulator and its clinician programmer.
Combines active-implantable engineering with a dedicated device cybersecurity team that prepares FDA premarket security documentation. Minimum engagement is not publicly disclosed. Works best with clients in Implantables & neuromodulation, Surgical & therapeutic devices, Wearables & remote monitoring.
Who should choose Phillips-Medisize?
A typical fit: autoinjector or pen injector development and production.
Design, molding and assembly of drug delivery devices under one global quality system. Minimum engagement is not publicly disclosed. Works best with clients in Drug delivery, Diagnostics & lab devices, Surgical & therapeutic devices.
Decision matrix: Velentium vs Phillips-Medisize
| Your situation | Recommended choice |
|---|---|
| You need full-ownership delivery on a defined project scope | Velentium |
| You need a large dedicated team for an ongoing programme | Check each company's engagement model |
| Your budget is at the lower end | Compare: Velentium (Not disclosed) vs Phillips-Medisize (Not disclosed) |
| You need specialist depth in a specific vertical | Velentium |
| You need staff augmentation or team extension | Neither; consider alternatives that offer staff aug |
| You need consulting before committing to a build | Both may offer discovery engagements |
Use case fit: Velentium vs Phillips-Medisize
| Use case | Velentium fit | Phillips-Medisize fit | Winner |
|---|---|---|---|
| Building a neurostimulator and its clinician programmer | Strong | Limited | Velentium |
| Preparing the cybersecurity section of an FDA 510(k) or PMA | Strong | Limited | Velentium |
| Autoinjector or pen injector development and production | Limited | Strong | Phillips-Medisize |
| Inhaler device for a pharma combination product | Limited | Strong | Phillips-Medisize |
Verdict: Velentium vs Phillips-Medisize
Velentium (4.5/5) is the stronger overall choice for most Medical Device Development projects. Combines active-implantable engineering with a dedicated device cybersecurity team that prepares FDA premarket security documentation.
Phillips-Medisize (3.9/5) is worth a look if you need inhaler device for a pharma combination product. If your situation matches that, Phillips-Medisize is a competitive option.
Related comparisons
Velentium vs Phillips-Medisize FAQ
Is Velentium better than Phillips-Medisize?
Velentium (4.5/5) scores higher overall, but "better" depends on your use case. Velentium's strongest advantage: cybersecurity is a full practice here, covering threat modeling, SBOMs, testing and postmarket monitoring. Phillips-Medisize's strongest advantage: very large manufacturing footprint across the US, Europe and Asia.
How do Velentium and Phillips-Medisize differ in pricing?
Velentium uses fixed project, time and materials, manufacturing contract pricing. Phillips-Medisize uses development contract plus manufacturing supply agreement pricing. Neither firm publishes a full rate card; a discovery call is required for project-specific quotes.
Which is better for enterprise: Velentium or Phillips-Medisize?
Velentium is the larger team and typically the better enterprise-scale choice. For very large programmes, verify team size and compliance coverage directly with each company before shortlisting.
What are the main differences between Velentium and Phillips-Medisize?
Velentium's primary differentiator is: combines active-implantable engineering with a dedicated device cybersecurity team that prepares FDA premarket security documentation. Phillips-Medisize's primary differentiator is: Design, molding and assembly of drug delivery devices under one global quality system. They also differ in team size (51–250 vs ~7,000), minimum engagement (Not disclosed vs Not disclosed), and primary industries served (Implantables & neuromodulation, Surgical & therapeutic devices vs Drug delivery, Diagnostics & lab devices).
Verify all details directly with each company before making a decision.